AG
MRVI icon

Algert Global’s Maravai LifeSciences MRVI Stock Holding History

Algert Global’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-131,599
Closed -$291K – 1278
2025
Q1 		$291K Sell
131,599
-15,860
-11% -$62.7K 0.01% 1018
2024
Q4 		$804K Buy
147,459
+45,741
+45% +$294K 0.02% 831
2024
Q3 		$845K Sell
101,718
-49,160
-33% -$425K 0.02% 786
2024
Q2 		$1.08M Buy
+150,878
New +$1.3M 0.04% 665
2023
Q2 		– Sell
-47,113
Closed -$660K – 1191
2023
Q1 		$660K Buy
47,113
+2,999
+7% +$43.1K 0.03% 763
2022
Q4 		$631K Sell
44,114
-28,040
-39% -$441K 0.04% 733
2022
Q3 		$1.84M Buy
72,154
+8,651
+14% +$217K 0.11% 295
2022
Q2 		$1.8M Buy
63,503
+3,479
+6% +$110K 0.14% 226
2022
Q1 		$2.12M Buy
60,024
+30,479
+103% +$1.02M 0.14% 225
2021
Q4 		$1.24M Buy
29,545
+21,155
+252% +$857K 0.15% 216
2021
Q3 		$412K Buy
+8,390
New +$409K 0.05% 621

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Algert Global's MRVI Position: Q2 2025 in Review

Algert Global sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 131,599 shares — an estimated $291K sold.

Algert Global first reported a position in MRVI in Q3 2021 and held it in 11 quarters. The position peaked at $2.12M in Q1 2022. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Algert Global reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 131,599 Maravai LifeSciences shares in Q2 2025, an estimated $291K.
  • Algert Global first reported a position in Maravai LifeSciences in Q3 2021 and held it in 11 quarters.
  • Algert Global's Maravai LifeSciences position peaked at $2.12M in Q1 2022.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.